ATE395082T1 - Antikörper gegen krebsantigen tmeff2 und seine anwendungen - Google Patents

Antikörper gegen krebsantigen tmeff2 und seine anwendungen

Info

Publication number
ATE395082T1
ATE395082T1 AT03744243T AT03744243T ATE395082T1 AT E395082 T1 ATE395082 T1 AT E395082T1 AT 03744243 T AT03744243 T AT 03744243T AT 03744243 T AT03744243 T AT 03744243T AT E395082 T1 ATE395082 T1 AT E395082T1
Authority
AT
Austria
Prior art keywords
antibodies
applications
cancer antigen
tmeff2
antigen tmeff2
Prior art date
Application number
AT03744243T
Other languages
English (en)
Inventor
Vinay Bhaskar
La Calle Agustin De
Debbie Law
Ingrid Caras
Vanitha Ramakrishnan
Richard Murray
Daniel Afar
David Powers
Original Assignee
Pdl Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pdl Biopharma Inc filed Critical Pdl Biopharma Inc
Application granted granted Critical
Publication of ATE395082T1 publication Critical patent/ATE395082T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03744243T 2002-03-08 2003-03-07 Antikörper gegen krebsantigen tmeff2 und seine anwendungen ATE395082T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36283702P 2002-03-08 2002-03-08
US43681202P 2002-12-27 2002-12-27

Publications (1)

Publication Number Publication Date
ATE395082T1 true ATE395082T1 (de) 2008-05-15

Family

ID=27807977

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03744243T ATE395082T1 (de) 2002-03-08 2003-03-07 Antikörper gegen krebsantigen tmeff2 und seine anwendungen

Country Status (15)

Country Link
US (5) US7288248B2 (de)
EP (1) EP1572087B1 (de)
JP (2) JP2006502092A (de)
KR (1) KR101104655B1 (de)
AT (1) ATE395082T1 (de)
AU (1) AU2003252830B2 (de)
CA (1) CA2478683C (de)
DE (1) DE60321041D1 (de)
DK (1) DK1572087T3 (de)
ES (1) ES2305481T3 (de)
IL (1) IL163902A0 (de)
PT (1) PT1572087E (de)
SI (1) SI1572087T1 (de)
WO (1) WO2003075855A2 (de)
ZA (1) ZA200407733B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990007806A (ko) * 1995-05-19 1999-01-25 벤슨로버트에이치 전환 성장 인자 α HII
US20040141983A1 (en) * 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
DE60321041D1 (de) * 2002-03-08 2008-06-26 Pdl Biopharma Inc Antikörper gegen krebsantigen tmeff2 und seine anwendungen
US20030180348A1 (en) * 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
WO2004067564A2 (en) 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
EP3434275A1 (de) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Auf die verwendung von auristatin-konjugaten mit antikörpern basierter nachweis für krebszellen
US20050175619A1 (en) * 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
MXPA06014065A (es) 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
US8901281B2 (en) 2005-06-17 2014-12-02 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
WO2007002525A2 (en) * 2005-06-28 2007-01-04 Schering Aktiengesellschaft Tomoregulin antibodies and uses thereof
AU2007345745C1 (en) 2006-06-19 2013-05-23 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
US20100285335A1 (en) * 2007-02-05 2010-11-11 Humphrey Samkelo Lungisani Sithebe Polycrystalline diamond (pcd) materials
ATE543835T1 (de) 2007-07-16 2012-02-15 Genentech Inc Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
ES2528922T3 (es) 2007-07-16 2015-02-13 Genentech, Inc. Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
AU2008312457B2 (en) * 2007-10-19 2014-04-17 Genentech, Inc. Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
EP3470534B1 (de) * 2009-01-07 2024-03-20 Arcedi Biotech ApS Anreicherung und identifizierung fötaler zellen aus maternalem blut und liganden für solch eine verwendung
US20110159588A1 (en) 2009-12-30 2011-06-30 Kui Lin Methods for Modulating a PDGF-AA Mediated Biological Response
EP3786185A1 (de) 2010-12-06 2021-03-03 Seagen Inc. Humanisierte antikörper gegen liv-1 und deren verwendung zur behandlung von krebs
US20150030602A1 (en) * 2011-12-23 2015-01-29 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
AU2017235545A1 (en) 2016-03-15 2018-10-25 Seagen Inc. Combination therapy using a LIV1-ADC and a chemotherapeutic
CR20200564A (es) * 2018-05-24 2021-06-21 Janssen Biotech Inc Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos
UA128273C2 (uk) 2019-06-07 2024-05-22 Арседі Байотек Апс Спосіб пренатальної діагностики (варанти)
JP2024503924A (ja) * 2021-01-27 2024-01-29 ヤンセン バイオテツク,インコーポレーテツド カリクレイン関連ペプチダーゼ2抗原結合ドメインを含む免疫コンジュゲート及びその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60321041D1 (de) * 2002-03-08 2008-06-26 Pdl Biopharma Inc Antikörper gegen krebsantigen tmeff2 und seine anwendungen

Also Published As

Publication number Publication date
WO2003075855A3 (en) 2006-03-23
US20080044840A1 (en) 2008-02-21
US7288248B2 (en) 2007-10-30
CA2478683C (en) 2016-01-26
US20040096392A1 (en) 2004-05-20
US8257708B2 (en) 2012-09-04
EP1572087A4 (de) 2006-11-02
US20110038864A1 (en) 2011-02-17
EP1572087A2 (de) 2005-09-14
IL163902A0 (en) 2005-12-18
WO2003075855A2 (en) 2003-09-18
AU2003252830B2 (en) 2008-10-09
US7824678B2 (en) 2010-11-02
AU2003252830A1 (en) 2003-09-22
PT1572087E (pt) 2008-07-11
US20080175846A1 (en) 2008-07-24
KR20050002848A (ko) 2005-01-10
US20080160012A1 (en) 2008-07-03
ZA200407733B (en) 2005-10-26
SI1572087T1 (sl) 2008-10-31
US7785816B2 (en) 2010-08-31
JP2006502092A (ja) 2006-01-19
EP1572087B1 (de) 2008-05-14
CA2478683A1 (en) 2003-09-18
ES2305481T3 (es) 2008-11-01
DK1572087T3 (da) 2008-08-25
DE60321041D1 (de) 2008-06-26
JP5192537B2 (ja) 2013-05-08
US7674883B2 (en) 2010-03-09
KR101104655B1 (ko) 2012-01-13
JP2011121950A (ja) 2011-06-23

Similar Documents

Publication Publication Date Title
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
ATE461220T1 (de) Anti-egfr-antikörper
EP1844077A4 (de) Dr5-antikörper und deren verwendung
CY1112862T1 (el) Θραυσματα μονοσθενους αντισωματος χρησιμα ως θεραπευτικα
CY1118369T1 (el) Αντισωματα εναντι cd38 για την θεραπεια πολλαπλου μυελωματος
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
CY1110759T1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
CY1116913T1 (el) Τροποποιημενα κλασματα fab αντισωματων
BR0011838A (pt) Elementos misturadores estáticos empilhados
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
TW200510459A (en) RG1 antibodies and uses thereof
TW200732349A (en) Anti-OX40L antibodies and methods using same
DK1629011T3 (da) Humane anti-humane-DC3-bindingsmolekyler
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
EA200701448A1 (ru) Специфически связывающаяся с крипто-антигеном человека молекула (варианты), композиция на ее основе (варианты), способ получения молекулы, способ лечения посредством молекулы (варианты) и способ ингибирования крипто-экспрессии в клетке больного
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
IL200404A (en) Conjugates of antibodies that bind 191p4d12(b)proteins and uses thereof for treating cancer
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
PT1644484E (pt) Células autólogas de indução de auto-tolerância de origem monocítica e sua utilização em preparações farmacêuticas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1572087

Country of ref document: EP